Cilostazol Enhances Mobilization of Circulating Endothelial Progenitor Cells and Improves Endothelium-Dependent Function in Patients at High Risk of Cardiovascular Disease

Ting Hsing Chao, I. Chih Chen, Cheng Han Lee, Ju Yi Chen, Wei Chuan Tsai, Yi Heng Li, Shih Ya Tseng, Liang Miin Tsai, Wei Kung Tseng

研究成果: Article同行評審

5 引文 斯高帕斯(Scopus)

摘要

This is the first study to investigate the vasculoangiogenic effects of cilostazol on endothelial progenitor cells (EPCs) and flow-mediated dilatation (FMD) in patients at high risk of cardiovascular disease (CVD). This double-blind, placebo-controlled study included 71 patients (37 received 200 mg/d cilostazol and 34 received placebo for 12 weeks). Use of cilostazol, but not placebo, significantly increased circulating EPC (kinase insert domain receptor+CD34+) counts (percentage changes: 149.0% [67.9%-497.8%] vs 71.9% ['31.8% to 236.5%], P =.024) and improved triglyceride and high-density lipoprotein cholesterol levels (P =.002 and P =.003, respectively). Plasma levels of vascular endothelial growth factor (VEGF)-A165 and FMD significantly increased (72.5% [32.9%-120.4%] vs '5.8% ['46.0% to 57.6%], P =.001; 232.8% ± 83.1% vs '46.9% ± 21.5%, P =.003, respectively) in cilostazol-treated patients. Changes in the plasma triglyceride levels significantly inversely correlated with the changes in the VEGF-A165 levels and FMD. Cilostazol significantly enhanced the mobilization of EPCs and improved endothelium-dependent function by modifying some metabolic and angiogenic markers in patients at high risk of CVD.

原文English
頁(從 - 到)638-646
頁數9
期刊Angiology
67
發行號7
DOIs
出版狀態Published - 2016 八月 1

All Science Journal Classification (ASJC) codes

  • 心臟病學與心血管醫學

指紋

深入研究「Cilostazol Enhances Mobilization of Circulating Endothelial Progenitor Cells and Improves Endothelium-Dependent Function in Patients at High Risk of Cardiovascular Disease」主題。共同形成了獨特的指紋。

引用此